Apellis Pharmaceuticals Provides Update on Two Phase Ib Trials for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
In All, PortfolioSeverely anemic patients with PNH on treatment with Soliris™ can become transfusion-free with improved hemoglobin when switched to APL-2 monotherapy. Treatment-naïve patients with PNH show clinically meaningful improvements for all hematological parameters when treated with APL-2. CRESTWOOD, Ky. and WALTHAM, Mass. — Apellis Pharmaceuticals, Inc. (Nasdaq:APLS),…